Literature DB >> 12218299

Expanded human tissue kallikrein family--a novel panel of cancer biomarkers.

George M Yousef1, Eleftherios P Diamandis.   

Abstract

The full characterization of the human kallikrein gene locus has allowed identification of all members of this gene family on chromosome 19q13.4 and the establishment of common structural criteria, at both the mRNA and protein level. The human kallikrein gene family now consists of 15 members; their mRNA and protein structure, tissue expression and hormonal regulation patterns have been delineated. In addition to prostate-specific antigen (PSA, hK3), which is an established tumor marker for prostate cancer diagnosis and follow-up, and human glandular kallikrein (hK2), an emerging prostate cancer biomarker, accumulating evidence indicates that many other members of the human kallikrein gene family are also implicated in endocrine-related malignancies. Many kallikreins are differentially regulated in breast, prostate, ovarian and testicular cancers. In addition, preliminary reports indicate that three newly identified kallikreins (hK6, hK10 and hK11) are serum biomarkers for diagnosis and monitoring of ovarian and prostate cancer. The mechanism by which kallikreins might be involved in the pathogenesis and/or progression of cancer is not as yet fully understood. Preliminary reports indicate a possible role of kallikreins in controlling vital processes, like apoptosis, angiogenesis and tumor metastasis by cleavage of critical substrates such as growth factors, hormones or extracellular matrix. In this review, we present data on the differential expression of kallikreins in cancer at both the mRNA and protein levels, and propose future directions of research towards our understanding of the involvement of kallikreins in cancer and their possible diagnostic, prognostic and therapeutic applications. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218299     DOI: 10.1159/000064027

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  17 in total

1.  Human Tissue Kallikreins in Polymorphous Adenocarcinoma: A Polymerase Chain Reaction and Immunohistochemical Study.

Authors:  Jacqueline Cox; Zia Khan; Linda Jackson-Boeters; Jerrold Armstrong; Mark Darling
Journal:  Head Neck Pathol       Date:  2020-06-26

Review 2.  Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system.

Authors:  Marxa L Figueiredo; Makoto Sato; Mai Johnson; Lily Wu
Journal:  Future Oncol       Date:  2006-06       Impact factor: 3.404

Review 3.  Advances in preclinical investigation of prostate cancer gene therapy.

Authors:  Marxa L Figueiredo; Chinghai Kao; Lily Wu
Journal:  Mol Ther       Date:  2007-04-24       Impact factor: 11.454

4.  Gingipains of Porphyromonas gingivalis Affect the Stability and Function of Serine Protease Inhibitor of Kazal-type 6 (SPINK6), a Tissue Inhibitor of Human Kallikreins.

Authors:  Karolina Plaza; Magdalena Kalinska; Oliwia Bochenska; Ulf Meyer-Hoffert; Zhihong Wu; Jan Fischer; Katherine Falkowski; Laura Sasiadek; Ewa Bielecka; Barbara Potempa; Andrzej Kozik; Jan Potempa; Tomasz Kantyka
Journal:  J Biol Chem       Date:  2016-06-27       Impact factor: 5.157

5.  Development of a multimarker assay for early detection of ovarian cancer.

Authors:  Zoya Yurkovetsky; Steven Skates; Aleksey Lomakin; Brian Nolen; Trenton Pulsipher; Francesmary Modugno; Jeffrey Marks; Andrew Godwin; Elieser Gorelik; Ian Jacobs; Usha Menon; Karen Lu; Donna Badgwell; Robert C Bast; Anna E Lokshin
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

Review 6.  -The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Int J Biol Markers       Date:  2011-09-21       Impact factor: 2.659

7.  Specificity of S'1 and S'2 subsites of human tissue kallikrein using the reactive-centre loop of kallistatin: the importance of P'1 and P'2 positions in design of inhibitors.

Authors:  Daniel C Pimenta; Sandro E Fogaça; Robson L Melo; Luiz Juliano; Maria A Juliano
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

8.  Blarina toxin, a mammalian lethal venom from the short-tailed shrew Blarina brevicauda: Isolation and characterization.

Authors:  Masaki Kita; Yasuo Nakamura; Yuushi Okumura; Satoshi D Ohdachi; Yuichi Oba; Michiyasu Yoshikuni; Hiroshi Kido; Daisuke Uemura
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

9.  KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.

Authors:  Konstantinos G Sidiropoulos; Qiang Ding; Georgios Pampalakis; Nicole M A White; Peter Boulos; Georgia Sotiropoulou; George M Yousef
Journal:  Mol Oncol       Date:  2016-04-08       Impact factor: 6.603

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.